Intro
What if together we could make improved healthspan,
performance, and longevity
accessible to everyone?
Mission
Cornucopian Capital – Seeding Medicine 3.0
At Cornucopian, we’re using long-term capital to build and support results-focused, high integrity companies that use scientific knowledge and accessible technologies to help everyone attain improved healthspan, enhanced performance, and extended longevity.
Our unique capabilities, strategic partnerships, institutional networks, and collaborators add meaningful value to early-stage companies seeking to deliver best-in-class health products and services to consumers, patients and healthcare providers.
Our Vision – A world where Medicine 3.0 is accessible to everyone.
Medicine is undergoing a paradigm shift from just treating disease to preventing it. A new generation of companies is increasing access to improved healthspan, performance, and longevity, while reducing risk for chronic diseases and treatments with diminishing returns. In doing so, these companies are redefining the multi-trillion dollar markets for health, wellness, and food.
Our Capabilities are rooted in our community – strategic partnerships, institutional networks, and collaborators who integrate leading science and technology with consumer-facing health products and services.
The Cornucopian community combines long-term relationships built on patient capital with leading academic resources, scientific expertise, entrepreneurs, and industry veterans aspiring to bring a new generation of health products and services to market.
Cornucopians are optimists combining creative and scientific potential withthe promise and genius of nature to seek better, innovative solutions for human health.
Our team works with results-focused urgency to support founders in the real investment of time and capital required to achieve evidence-based quality. Are you a Cornucopian?
Connect with us if you’re interested in growing, partnering, and collaborating with us.
We invest in all early VC stages from pre-Seed to Series B+ company financings with initial check sizes ranging from $250,000 to $2.5M.